Improving the treatment of breathlessness – a phase III randomised, controlled trial of sustained release morphine for the symptomatic treatment of chronic refractory breathlessness. A Palliative Care Clinical Studies Collaborative study

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1065571

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

More than 300000 Australians are chronically short of breath at rest or on minimal exertion despite optimal treatment of the underlying causes of their breathlessness, of whom 70000 cannot leave home. No medication in the world is registered to treat this. There is evidence that regular, low dose morphine safely helps breathlessness. This study will help clinicians adjust doses more effectively and understand whether using an additional medication to reduce anxiety helps relieve breathlessness.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $902,732.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

benzodiazepines | dyspnoea | genetic variation | opioids | pharmacodynamics | randomised controlled trial (RCT)

Related Links